(2003; 67 pages)
1. Matteelli A. et al. In vivo sensitivity of Plasmodium falciparum to chloroquine, amodiaquine and sulfadoxine/pyrimethamine, Zanzibar, United Republic of Tanzania. Geneva, World Health Organization, 1990. (WHO/MAL/90.1055).
2. Walker GJA, Hogerzeil HV. Potency of ergometrine in tropical countries. Letter to the Editor. Lancet, 1988, ii: 393.
3. Hogerzeil HV, Walker GJA. Instability of (methyl) ergometrine in tropical climates: an overview. European Journal of Obstetrics Gynecology and Reproductive Biology, 1996, 69: 25-29.
4. Hogerzeil HV et al. Stability of essential drugs during shipment to the tropics. Letter to the Editor. British Medical Journal, 1992, 304: 210-212.
5. Nazerali H, Hogerzeil HV. The quality and stability of essential drugs in rural Zimbabwe: controlled longitudinal study. British Medical Journal, 1998, 317: 512-513.
6. Wondemagegnehu E. Counterfeit and substandard drugs in Myanmar and Viet Nam. Geneva, World Health Organization; 1999. (WHO/EDM/QSM/99.3).
7. World Health Organization. Guidelines for the development of measures to combat counterfeit drugs, DMP-DAP Joint Project on Counterfeit Drugs. Geneva, World Health Organization, 1999. (WHO/EDM/QSM/99.1).
8. World Health Organization. Monitoring antimalarial drug resistance. Geneva, World Health Organization, 2002. (WHO/CDS/CSR/EPH/2002.17 and WHO/CDS/RBM/2002.39).